PHILADELPHIA, PA--(Marketwire - July 29, 2010) -  Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today that John Fraher, Chief Commercial Officer, is scheduled to present at the Bank of America Merrill Lynch Specialty Pharmaceuticals Conference. Details are as follows:

A live audio webcast of the presentation can be accessed in the investor relations section of Eurand's web site at www.eurand.com and will be available via replay for 30 days.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles and taste-masking orally disintegrating tablet (ODT) formulations. Eurand is a global company with facilities in the U.S. and Europe. For more information, visit www.eurand.com.